Read our Recent Headlines

October 16 Biotech Update

Some good news today and most was unexpected. Some needs more discussion than other but I want to touch on all of them. Ideally this will be the catalysts needed.

October 9th Biotech Update

We are potentially setting up well for the sector. Yesterday was a down day but was that the pullback to consolidate the bounce and start a trend higher? Maybe. We.

October 8 Biotech Update

This is going to be an interesting couple of days for the sector. This is either the pullback to consolidate before another leg higher or the end of the dead.

October 7 Biotech Update

Not a lot of news to start the week. Some interesting odds and ends but nothing to really be a sector mover, so I suspect it continues with the trend.

October 2 Biotech Update

Today seems like a reversal day. The sector has been down for 11 straight trading sessions and is at a support level. I would have thought that $74 on the.

October 1 Biotech Update

We are probably due for a bounce in the sector as it has almost been straight down for a little bit. I think the $84 level on the XBI looks.

September 30 Biotech Update

The sector continued to underperform. I suspect part of this is a continuation of the overall underperformance and part is increasing fear around Warren’s rise in the polls. That is.


[videojs width="640" preload="auto" ogg="" webm="" mp4=""]


Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!